Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929576 | 0.86 | CA12 (0.41) | HTR6CA12CA9CA2PIK3CD | |
| SCHEMBL6117267 | 0.78 | CA12 (0.55) | HTR6CA12CA9CA2ACLY | |
| SCHEMBL5801948 | 0.74 | HTR6 (0.48) | HTR6CA12CA9CA2ACLY | |
| SCHEMBL2928503 | 0.73 | HTR6 (0.47) | HTR6ACLYTP53MAPTSMN1; SMN2 | |
| SCHEMBL2925579 | 0.72 | HTR6 (0.40) | HTR6CA12CA9CA2CREBBP | |
| SCHEMBL2928793 | 0.72 | HTR6 (0.41) | HTR6CREBBPTP53MAPTSMN1; SMN2 | |
| SCHEMBL2925787 | 0.70 | CCR2 (0.52) | HTR6ACLYMAPTPPARGPPARA | |
| SCHEMBL2927942 | 0.70 | HTR6 (0.40) | HTR6CA12CA9CA2ACLY | |
| SCHEMBL2954808 | 0.69 | HDAC3 (0.47) | HTR6MAPTPPARGPPARAPPARD | |
| SCHEMBL2927852 | 0.68 | HTR6 (0.43) | HTR6CA12CA9CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086950-B1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-23 | — | — | US | disclosed |
| US-6875770-B2 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6673797-B1 | CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1086950-A1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | PTGS2, IDO2, IDO1 | HTR6 171/4885CA12 1222/4885CA9 396/4885 |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | IDO1, PTGS1, IDO2 | HTR6 165/4885CA12 2770/4885CA9 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.